FAQs - Clearity Foundation - Tumor Blueprint testing (assistance info - see website)

Clearity Foundation Tumor Blue Print

 Who Should Be Tested?

Initial treatment for ovarian cancer typically includes surgery followed by chemotherapy drugs such as Carboplatin and Taxol. This treatment is effective in the majority of women, but, unfortunately, the cancer frequently comes back and a new treatment is required. Recurrent cancer is likely to require different treatment because tumors turn on other pathways and become resistant to some chemotherapies.
For women with recurrent or refractory ovarian cancer, a Tumor Blueprint is generated using a tumor specimen from the recurrent cancer which provides information to help guide the selection of therapy options, including identification of appropriate clinical trials.
Tumor profiling is most likely to be useful if one of the following statements describes your situation:

• “I am having a recurrence since my first diagnosis and my doctor has planned another surgery or a biopsy to remove tumor tissue.”
• “I have had a recurrence since my first diagnosis and another surgery or biopsy was performed to remove tumor tissue during the last year.”
• “I have had a recurrence or my cancer progressed within a year of my first diagnosis.”
• “I was recently diagnosed with advanced stage (stage III or IV) ovarian cancer that is clear cell or mucinous histology or carcinosarcoma.”

The Clearity Foundation has partnered with clinical laboratories that perform tumor testing. In order to conduct testing, a small piece of tumor tissue is needed. If you have a biopsy planned, please contact us ahead of time to ensure that sufficient sample is collected. Our team will work with your physician to arrange for the tumor sample to be tested.

FAQs - Clearity Foundation
  Who performs the biomarker testing?
The Clearity Foundation has established relationships with CLIA-certified clinical labs to perform the testing. Currently, our partners include Caris Life Sciences, Clarient, Inc., and Foundation Medicine, Inc.